ASP Isotopes, Inc. (ASPI) AI Stock Analysis

• Market Cap: $906.26M
• Dividend Yield: N/A
• Average Volume (3M): 4.92M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.03
• Revenue Growth: 99.57%
• EPS Growth: -126.31%
• Country: US
• Employees: 136
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals
• EPS (TTM): -0.64
• Shares Outstanding: 91,913,110
• 10 Day Avg. Volume: 4,295,302
• 30 Day Avg. Volume: 4,922,584
• PEG Ratio: -0.27
• Price to Book (P/B): 5.27
• Price to Sales (P/S): 60.85
• P/FCF Ratio: -8.99
• Enterprise Value/Market Cap: 0.34
• Enterprise Value/Revenue: 68.01
• Enterprise Value/Gross Profit: 173.23
• Enterprise Value/Ebitda: -3.15
• 1Y Price Target: $10.50
• Price Target Upside: -6.42% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 58 Neutral
• Price Target: $11.50 ▲(2.50% Upside)

ASP Isotopes, Inc. has a mixed outlook. The most significant factor is its financial performance, which shows revenue growth but struggles with profitability and cash flow. Technical analysis is positive, indicating bullish momentum, but valuation concerns due to negative earnings weigh heavily. The earnings call highlights both opportunities and challenges, adding to the uncertainty.

Positive Factors

Revenue Growth

The significant revenue increase from 2023 to 2024 demonstrates ASP Isotopes' expanding market reach and product adoption, which is crucial for long-term growth in the isotopes industry.

Expansion Plans

The expansion into new facilities indicates ASP Isotopes' commitment to increasing production capacity, which could enhance its competitive position and market share in the isotopes sector.

Strong Cash Position

A robust cash position provides ASP Isotopes with the financial flexibility to invest in growth initiatives and weather operational challenges, supporting long-term business stability.

Negative Factors

Profitability Challenges

Ongoing profitability issues indicate that ASP Isotopes needs to improve operational efficiency to ensure sustainable financial health and shareholder value.

Regulatory Delays

Delays in regulatory approvals can hinder ASP Isotopes' ability to execute expansion plans, affecting its growth trajectory and competitive positioning in the industry.

Negative Cash Flow

Negative cash flows indicate difficulties in generating cash from operations, which may limit ASP Isotopes' ability to fund growth and meet financial obligations, posing a risk to long-term viability.

ASP Isotopes, Inc. Business Overview & Revenue Model

Company Description

ASP Isotopes Inc., a pre-commercial stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It develops Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company also Uranium-235, an isotope of uranium for carbon-free energy industry. ASP Isotopes Inc. was incorporated in 2021 and is based in Boca Raton, Florida.

How the Company Makes Money

ASP Isotopes, Inc. generates revenue primarily through the sale of its isotopic products to a diverse customer base that includes hospitals, research institutions, and industrial companies. The company leverages its expertise in isotope production to supply medical isotopes used in diagnostic imaging and cancer treatment, as well as industrial isotopes for applications such as radiography and material analysis. ASP Isotopes may also engage in strategic partnerships and supply agreements to enhance its market reach and secure long-term revenue streams. Additionally, the company might explore opportunities for licensing its technology or collaborating on research projects to further augment its income.

ASP Isotopes, Inc. Financial Statement Overview

Summary

ASP Isotopes, Inc. shows significant revenue growth but faces ongoing challenges with profitability and cash flow generation. The balance sheet is moderately leveraged with a strong cash position, yet profitability issues and negative cash flows highlight potential risks.

Income Statement

ASP Isotopes, Inc. has struggled with profitability as evidenced by persistently negative net income and EBIT across multiple years. The gross profit margin for the latest annual report is 38.6%, but the net profit margin is severely negative at -847.4%, indicating significant costs and expenses relative to revenue. There is, however, a significant increase in total revenue from 2023 to 2024, but given the high losses, revenue growth has not yet translated into profitability.

Balance Sheet

The company's balance sheet shows a moderate debt-to-equity ratio of 0.79, suggesting some reliance on debt for financing, but not excessively so. Equity represents about 50.7% of total assets, indicating a balanced capital structure. The cash position is strong with cash and equivalents exceeding total debt, providing a cushion for financial obligations. However, the persistently negative net income raises concerns about long-term equity value.

Cash Flow

ASP Isotopes, Inc. is experiencing negative operating and free cash flows, reflecting challenges in generating cash from operations. The operating cash flow to net income ratio is negative, aligning with the ongoing losses. Free cash flow is also negative, indicating that the company is not generating sufficient cash to cover capital expenditures, which could impact future growth initiatives.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	4.58M	4.14M	433.03K	0.00	0.00
Gross Profit	1.80M	1.60M	138.97K	-72.57K	-19.38K
EBITDA	-98.78M	-31.58M	-16.14M	-4.87M	-2.59M
Net Income	-99.96M	-32.33M	-16.29M	-4.79M	-2.61M
Balance Sheet
Total Assets	135.91M	94.35M	30.19M	12.50M	7.14M
Cash, Cash Equivalents and Short-Term Investments	67.68M	61.89M	7.91M	2.39M	2.95M
Total Debt	101.69M	37.75M	2.14M	822.20K	926.60K
Total Liabilities	107.60M	43.18M	11.36M	2.68M	1.14M
Stockholders Equity	25.23M	47.90M	16.30M	9.82M	6.00M
Cash Flow
Free Cash Flow	-31.28M	-28.07M	-7.74M	-7.41M	-3.57M
Operating Cash Flow	-19.67M	-16.70M	-5.41M	-2.94M	-577.69K
Investing Cash Flow	-42.42M	-11.37M	-2.45M	-4.47M	-2.99M
Financing Cash Flow	100.87M	82.53M	13.39M	6.64M	6.50M

ASP Isotopes, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 11.22
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ASPI, the sentiment is Positive. The current price of 11.22 is above the 20-day moving average (MA) of 9.16, above the 50-day MA of 9.39, and above the 200-day MA of 6.68, indicating a bullish trend. The MACD of 0.14 indicates Negative momentum. The RSI at 66.60 is Neutral, neither overbought nor oversold. The STOCH value of 87.95 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ASPI.

ASP Isotopes, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ASIX	70 Outperform	535.81M	7.19	9.39%	3.21%	1.31%	796.76%
VHI	68 Neutral	465.01M	4.78	9.16%	1.95%	4.04%	283.22%
ASPI	58 Neutral	$906.26M	―	-551.61%	―	99.57%	-126.31%
LXU	54 Neutral	584.84M	-17.56	-6.69%	―	2.60%	-1506.69%
FF	54 Neutral	172.15M	-6.51	0.00%	6.11%	-51.14%	-165.98%
RYAM	50 Neutral	469.01M	-1.05	-129.65%	―	-4.90%	-458.80%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%

ASP Isotopes, Inc. Corporate Events

ASP Isotopes Expands Board with New Appointment

On September 6, 2025, ASP Isotopes Inc. expanded its Board of Directors to seven members, appointing Ralph L. Hunter as a Class II director, effective September 8, 2025. Mr. Hunter, with over 35 years of experience in the nuclear sector, is expected to bring valuable expertise to the company, enhancing its strategic positioning in the industry.

ASP Isotopes Plans Johannesburg Stock Exchange Listing

ASP Isotopes Inc. announced a corporate access event for South African investors on August 26, 2025, ahead of its secondary listing on the Johannesburg Stock Exchange, which is set to commence on August 27, 2025. The company is making significant strides in its isotope enrichment operations, with commercial production of Silicon-28 and Ytterbium-176 already underway and plans to expand its capabilities for other isotopes. Despite some delays in transitioning to semi-continuous processing for Ytterbium-176 and regulatory inspections affecting Carbon-12 production, the company is poised to enhance its production capacity and meet growing demand. Additionally, ASP Isotopes is preparing to spin out its Quantum Leap Enrichment subsidiary and finalize the acquisition of Renergen in the latter half of 2025.